Engineers Gate Manager LP Sells 81,590 Shares of Edwards Lifesciences Corporation $EW

Engineers Gate Manager LP cut its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 37.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 137,294 shares of the medical research company’s stock after selling 81,590 shares during the period. Engineers Gate Manager LP’s holdings in Edwards Lifesciences were worth $12,420,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of the stock. California State Teachers Retirement System increased its position in shares of Edwards Lifesciences by 9,187.8% during the 2nd quarter. California State Teachers Retirement System now owns 80,962,062 shares of the medical research company’s stock valued at $7,323,828,000 after purchasing an additional 80,090,362 shares during the last quarter. BlackRock Inc. bought a new stake in Edwards Lifesciences in the second quarter worth $5,318,092,000. State Street Corp boosted its stake in Edwards Lifesciences by 1.5% during the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after buying an additional 371,892 shares during the period. Wellington Management Group LLP boosted its stake in Edwards Lifesciences by 4.8% during the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock worth $1,857,934,000 after buying an additional 989,533 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in Edwards Lifesciences during the second quarter valued at $1,274,082,000. 79.46% of the stock is owned by institutional investors.

Insider Activity

In other news, VP Daniel Lippis sold 619 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Brüls sold 2,644 shares of Edwards Lifesciences stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the sale, the vice president owned 17,984 shares of the company’s stock, valued at $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 5,045 shares of company stock worth $457,749. Company insiders own 0.31% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on EW. TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Friday, July 17th. Mizuho lifted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Finally, UBS Group assumed coverage on shares of Edwards Lifesciences in a research note on Tuesday, July 28th. They set a “buy” rating and a $110.00 target price for the company. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average price target of $100.27.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $86.69 on Friday. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The company has a market capitalization of $49.92 billion, a PE ratio of 49.82, a P/E/G ratio of 2.26 and a beta of 0.85. The company has a 50 day moving average price of $89.36 and a 200-day moving average price of $85.80. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.Edwards Lifesciences’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period last year, the business posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.